A Phase 4 interventional study of Zinc Sulfate 110 MG (Zinc 25 MG) Oral Tablet in Benign Migratory Glossitis, sponsored by mariam hamouda. Completed at 1 site in Egypt. Open to participants aged 18 Years to 60 Years. Per ClinicalTrials.gov, last updated 2023-08-01.
Sponsored by mariam hamouda · Phase 4, Interventional, and Treatment
Effectiveness of Zinc Supplementation in management of patients with symptomatic Benign Migratory Glossitis.
Zinc supplements seems to be a therapeutic option as Migratory glossitis is a chronic disease knowing that it needs no treatment. Zinc deficiency can probably be a causative factor in filiform papillae atrophy. Studies have mentioned the role of zinc in wound healing and maintaining a healthy epithelium, as well as regeneration of filiform papillae. Geographic tongue is a disorder that affects the lingual papillae. It has been shown that zinc sulfate can contribute to the treatment of geographic tongue positively.
Forty-eight patients diagnosed with symptomatic benign migratory glossitis will be selected from Oral Medicine, Periodontology and Oral Diagnosis department, Faculty of dentistry, Ain shams university. Research ethical committee will review the protocol and the procedure will be explained to the patients and they will sign an informed consent.
Seven days after the diagnosis and selection of patients with (BMG), the atrophic areas will be determined and the patients will attend a control checkup in order to exclude those with constant changing patterns of the red atrophic areas with raised keratotic margins. Only those patients who presented with constant atrophic areas with keratotic margins at the control checkup will be included during the study evaluation process, then the selected patient according the following inclusion and exclusion criteria will be randomly allocated into two groups. Patients met the eligibility criteria will be randomly assigned for 2 different groups using computer generated allocation concealment. Group I: Will include 24 patients with symptomatic BMG receiving Zinc Supplementation once daily and zinc rich diet for one month. (study group).Group II: Will include 24 patients with symptomatic BMG receiving zinc rich diet only For one month. (control group). Intensity of the discomfort will be monitored by the patients using the Visual Analogue Scale (VAS). Saliva will be collected from all included patients to evaluate zinc levels before treatment and one month after treatment only.
25 studies on the registry are indexed under Glossitis, Benign Migratory; 4 are open to participants now.
This study's enrollment of 48 is below the median of 200 across 13 interventional studies indexed under Glossitis, Benign Migratory.
Browse Glossitis, Benign Migratory studies →This is the only study on the registry with mariam hamouda as lead sponsor.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Zinc Sulphate 25 Mg once daily for one month
Drug: Zinc Sulfate 110 MG (Zinc 25 MG) Oral Tablet
Zinc sulfate is an inorganic compound. It is used as a dietary supplement to treat zinc deficiency and to prevent the condition in those at high risk
Also known as: Octozinc
Clinical Score
the size of atrophic areas
Time frame: change from baseline at 8 weeks
Subjective Scale
intensity of symptoms
Time frame: change from baseline at 8 weeks
Biochemical
salivary zinc levels
Time frame: change from baseline at 4 weeks
Plan to share: No
No publications or documents are linked to this record.
Ran from Sep 2021 to primary completion in Jan 2022, 4 months.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jul 2023. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Zinc Sulfate